OKUR
OnKure Therapeutics, Inc.3.0200
-0.1800-5.63%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
40.92MP/E (TTM)
-Basic EPS (TTM)
-4.68Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
OnKure advances OKI-219 trials
OnKure Therapeutics reported Q2 2025 financials, posting a $15.4 million net loss amid ramped-up R&D spending of $12.6 million, while cash reserves stood at $83.4 million to fund operations into Q4 2026. The company advanced its PIKture-01 trial for OKI-219, completing enrollment in monotherapy and fulvestrant arms with data due in Q4 2025, and launched new triplet arms combining OKI-219 with ribociclib for HR+ breast cancer and tucatinib for HER2+ cases. Progress accelerates in precision oncology. Yet risks loom from clinical uncertainties.
10-Q
Q2 FY2025 results
OnKure Therapeutics posted a Q2 net loss of $15.4M, up 8.9% y/y from $14.1M, driven by R&D expenses climbing 17.4% to $12.6M on heightened clinical trial and manufacturing costs for OKI-219, while G&A edged up 3.3% to $3.7M amid share-based compensation. For the half-year, losses widened to $31.3M from $23.7M y/y, with operating cash burn at $27.3M versus $17.1M, yielding free cash flow of -$27.3M (derived). Cash dwindled to $83.4M from $110.8M at year-end, funding operations into late 2026; no debt burdens the balance sheet. The October 2024 merger with Legacy OnKure closed for $65M in stock and cash, folding in $57.7M cash with no goodwill recognized. Yet clinical trial setbacks could stall OKI-219 progress.
IPO
Employees
Sector
Industry
AURA
Aura Biosciences, Inc.
6.18-0.15
KURA
Kura Oncology, Inc.
10.63+0.07
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MURA
Mural Oncology plc
2.04+2.04
NXTC
NextCure, Inc.
11.12-0.35
OKYO
OKYO Pharma Limited
1.88-0.01
ONCY
Oncolytics Biotech Inc.
1.04+0.12
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
XCUR
Exicure, Inc.
6.06+0.33